Loading...
XNASLIVN
Market cap2.54bUSD
Dec 24, Last price  
46.75USD
1D
-0.51%
1Q
-9.61%
Jan 2017
3.96%
IPO
-27.12%
Name

LivaNova PLC

Chart & Performance

D1W1MN
XNAS:LIVN chart
P/E
144.68
P/S
2.20
EPS
0.32
Div Yield, %
0.00%
Shrs. gr., 5y
2.25%
Rev. gr., 5y
0.83%
Revenues
1.15b
+12.89%
110,721,499103,442,570123,441,575130,968,437121,229,742143,600,979167,775,672190,464,398218,502,731254,320,417282,014,160291,557,9981,213,900,0001,012,300,0001,107,000,0001,084,200,000934,200,0001,035,400,0001,021,800,0001,153,545,000
Net income
18m
P
6,759,509-12,218,348-59,069,192-51,180,107-10,334,76526,720,62078,448,88446,725,71036,077,73246,357,50254,890,25757,847,534-62,800,000-25,100,000-189,400,000-155,500,000-343,300,000-135,700,000-86,200,00017,546,000
CFO
75m
+7.17%
3,595,349-3,969,672-70,876,209-20,688,85614,455,20724,589,95042,885,48649,872,10775,026,16579,053,75954,195,81679,675,11690,200,00091,300,000120,500,000-91,100,000-79,400,000102,500,00069,900,00074,914,000
Earnings
Feb 19, 2025

Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
URL
https://www.livanova.com/en-us
IPO date
Oct 19, 2015
Employees
2,900
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122015‑04
Income
Revenues
1,153,545
12.89%
1,021,800
-1.31%
1,035,400
10.83%
Cost of revenue
576,112
470,400
512,800
Unusual Expense (Income)
NOPBT
577,433
551,400
522,600
NOPBT Margin
50.06%
53.96%
50.47%
Operating Taxes
(98,876)
11,100
11,200
Tax Rate
2.01%
2.14%
NOPAT
676,309
540,300
511,400
Net income
17,546
-120.35%
(86,200)
-36.48%
(135,700)
-60.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
(7,503)
(8,700)
309,700
BB yield
0.27%
0.29%
-7.00%
Debt
Debt current
26,473
23,400
229,700
Long-term debt
659,319
577,100
81,600
Deferred revenue
3,874
19,100
Other long-term liabilities
191,454
229,826
136,900
Net debt
396,445
370,000
86,700
Cash flow
Cash from operating activities
74,914
69,900
102,500
CAPEX
(34,981)
(26,500)
(25,500)
Cash from investing activities
(40,331)
(38,400)
36,900
Cash from financing activities
21,484
280,100
(181,500)
FCF
281,299
484,500
575,100
Balance
Cash
266,504
214,200
208,000
Long term investments
22,843
16,300
16,600
Excess cash
231,670
179,410
172,830
Stockholders' equity
(911,834)
(949,725)
(822,666)
Invested Capital
3,021,320
2,945,525
2,533,566
ROIC
22.67%
19.72%
19.40%
ROCE
27.22%
27.51%
30.41%
EV
Common stock shares outstanding
54,212
53,472
50,633
Price
51.74
-6.84%
55.54
-36.47%
87.43
32.05%
Market cap
2,804,929
-5.55%
2,969,835
-32.91%
4,426,843
37.60%
EV
3,201,374
3,339,835
4,513,543
EBITDA
638,289
609,200
590,500
EV/EBITDA
5.02
5.48
7.64
Interest
58,853
48,300
49,700
Interest/NOPBT
10.19%
8.76%
9.51%